Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Last trade$22.35
Day change-$1.825 (-7.55%)
Day range$22.19 – $24.77
Volume961,683
Market cap$4.10B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.1B
Price / earnings
—
Price / book
4.18×
Price / sales
—
EV / sales
—
EV / EBITDA
-17.68×
Profitability
Earnings per share
-$1.23
Return on assets
-20.13%
Return on equity
-21.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
39.45×
Quick ratio
39.45×
Cash ratio
3.45×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$150.36M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TNGX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$53.81M
$3.18M
$5.39M
$4.12M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$53.81M
$3.18M
$5.39M
$4.12M
Selling, general and administrative
$29.19M
$22.59M
$15.24M
$9.76M
$8.92M
$11.34M
$11.48M
$11.09M
Research and development
$48.93M
$37.2M
$33.53M
$32.1M
$30.82M
$32.81M
$36.44M
$33.94M
Total operating expenses
$78.12M
$59.79M
$48.77M
$41.86M
$39.74M
$44.15M
$47.92M
$45.03M
Operating income
-$78.12M
-$59.79M
-$48.77M
-$41.86M
$14.07M
-$40.97M
-$42.53M
-$40.91M
Interest expense
$0
$0
$0
$1.68M
$0
$0
$0
$1.81M
Income before taxes
-$68.39M
-$55.34M
-$45.51M
-$38.8M
$15.87M
-$38.82M
-$39.84M
-$37.62M
Income taxes
$0
$1K
$1K
-$55K
-$10K
$35K
$34K
$49K
Net income
-$68.39M
-$55.34M
-$45.51M
-$38.75M
$15.88M
-$38.85M
-$39.88M
-$37.67M
Net income attributable to common shareholders
-$68.39M
-$55.34M
-$45.51M
-$38.75M
$15.88M
-$38.85M
-$39.88M
-$37.67M
EBITDA
-$77.7M
-$59.36M
-$48.31M
-$41.39M
$14.63M
-$40.34M
-$41.91M
-$40.29M
Basic earnings per share
-$0.39
-$0.37
-$0.32
-$0.29
$0.14
-$0.35
-$0.36
-$0.34
Diluted earnings per share
-$0.39
-$0.37
-$0.32
-$0.31
$0.13
-$0.35
-$0.36
-$0.34
Recent news
Company coverage with links to the original publishers.
Tango Therapeutics shares dropped 16.4% after updated phase I/II data showed an 82% objective response rate in pancreatic cancer, down from 92% in June's initial readout. While the combination demonstrated durable disease control with 88% nine-month progression-free survival, the company also announced a 14% workforce reduction and R&D reprioritization focusing on PRMT5 programs. Tango plans to initiate a phase III study in 2027.
Tango, a global live-streaming platform, has donated tens of thousands of dollars to FRIDA Ukraine to support the OncoBus mobile cancer screening initiative. The program brings cancer detection services, specialist consultations, and medical training to underserved communities in Ukraine, having already served 230+ patients and identified 25 potential oncology cases.
Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026.
Tango Therapeutics (TNGX) stock has declined 6.2% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a wider-than-expected loss of 37 cents per share due to higher operating expenses, with R&D expenses up 13% and G&A expenses nearly doubling. Collaboration revenues dropped to zero from $3.2 million year-over-year following the conclusion of its Gilead partnership. Analyst estimates have shifted downward by 10.16% in the past month, and the stock carries a Zacks Rank #3 (Hold) with poor VGM scores across growth, momentum, and value metrics.
A new retail real estate portfolio execution index reveals that nearly all large retailers (97.6%) experience downstream problems from lease management decisions. The report finds that retailers manage roughly one major real estate project per week, but only 17% receive automated alerts for lease deadlines. Retailers using integrated third-party systems report significantly higher satisfaction (47%) compared to those using disconnected systems (19%), highlighting the competitive advantage of portfolio-level visibility and coordination.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.